Your session is about to expire
← Back to Search
Text Reminders for Psoriasis Treatment Adherence
N/A
Recruiting
Led By Steven R Feldman, MD, PhD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients with moderate-to-severe plaque psoriasis. Standard criteria for moderate-to-severe plaque psoriasis will be used (BSA greater than or equal to 3% or face/palm/sole/genital involvement or severe effect on Quality of Life).
Subject must be 18 years of age or older.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 month close-out visit
Awards & highlights
Study Summary
This trial will explore why psoriasis patients are not following topical treatments and ways to improve adherence to improve treatment outcomes.
Who is the study for?
This trial is for adults with moderate-to-severe plaque psoriasis who speak English and can use approved birth control if necessary. They must have a TB test done at baseline. People with other skin conditions, pregnant or breastfeeding women, those without this type of psoriasis, under 18s, patients with severe health issues or cancer in the last 5 years, on certain other psoriasis treatments, or with recent substance abuse problems cannot join.Check my eligibility
What is being tested?
The study tests whether text reminders can help people stick to their treatment plan for deucravacitinib better than no reminders. Forty patients will be split into two groups: one receiving reminders and the other not. The study aims to understand what makes someone more likely to follow their treatment and compare how well the drug works between these two groups.See study design
What are the potential side effects?
While specific side effects are not listed here as it's an adherence study rather than a drug trial per se, generally speaking deucravacitinib may cause infections due to immune system effects; however, participants should discuss potential side effects of deucravacitinib with their healthcare provider.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have moderate-to-severe plaque psoriasis affecting my quality of life or certain body areas.
Select...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 month close-out visit
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 month close-out visit
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Identify Adherence to treatment
Secondary outcome measures
Disease Clarity - Investigator's Global Assessment (IGA) Scale
Psoriasis Treatment Efficacy (PASI 100)
Psoriasis Treatment Efficacy (PASI 75)
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
50% of subjects will be randomized to a reporting tool designed to promote better adherence to treatment by having subjects report their progress on a weekly basis (the goal is not to test this tool but to help assure there is a broad range of adherence behavior including some positive adherence outliers)
Group II: No InterventionActive Control1 Intervention
50% of subjects will not receive additional outreach to improve adherence
Find a Location
Who is running the clinical trial?
Wake Forest University Health SciencesLead Sponsor
1,243 Previous Clinical Trials
1,004,686 Total Patients Enrolled
12 Trials studying Psoriasis
963 Patients Enrolled for Psoriasis
Bristol-Myers SquibbIndustry Sponsor
2,641 Previous Clinical Trials
4,130,024 Total Patients Enrolled
36 Trials studying Psoriasis
20,040 Patients Enrolled for Psoriasis
Steven R Feldman, MD, PhDPrincipal InvestigatorWake Forest University Health Sciences
14 Previous Clinical Trials
563 Total Patients Enrolled
4 Trials studying Psoriasis
171 Patients Enrolled for Psoriasis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have moderate-to-severe plaque psoriasis.I am under 18 years old.I am 18 years old or older.I do not have any severe or unstable health conditions.I have moderate-to-severe plaque psoriasis affecting my quality of life or certain body areas.I am currently using treatments like biologics or phototherapy for psoriasis.I have not had any cancer except for certain skin cancers in the last 5 years.I do not have skin conditions that could affect skin test results.You need to have a test to check for tuberculosis before starting the study.You have been actively abusing drugs or alcohol, or have a history of doing so within the past 6 months.I have a history of severe depression or thoughts of suicide.I have been tested for tuberculosis.
Research Study Groups:
This trial has the following groups:- Group 1: Intervention
- Group 2: No Intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Can I take part in the current clinical investigation?
"To be eligible for this trial, individuals must have psoriasis and fit under the age parameters of 18 to 75 years. The research team is recruiting a total of 40 patients."
Answered by AI
Are those aged 50+ eligible for participation in this experiment?
"This research is recruiting individuals older than 18 and younger than 75."
Answered by AI
Are there any available vacancies within the framework of this research?
"According to information recorded on clinicaltrials.gov, this study is not presently searching for volunteers; it was first posted in December 1st 2022 and edited lastly October 12th 2022. Although the current trial does not require participants, there are 169 other studies taking part which need applicants."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger